This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Osteoporosis  • Statistics and Research Methods  • Neurology  • Alzheimer Disease  • Randomized Controlled Trial  • Stroke  • Alert me on articles by topic

Yoshihiro Sato, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

Although it was described that the study was done in a single hospital, I requested my physician colleagues of other nearby hospitals to participate in the 2 studies. Therefore, regarding the study on AD,¹ we actually had 2 collaborating hospitals, and each of them followed 195 and 93 patients. The remaining 212 patients were followed at Mitate Hospital, Tagawa, Japan. Similarly, in the stroke study,² the 2 collaborating hospitals followed 123 and 81 patients, and the remaining 76 patients were from Mitate Hospital. I apologize for confusing the readers of the ARCHIVES by not providing the numbers of patients in other hospitals involved in the studies. The authors did not describe this fact, the reason being that these hospitals were reluctant to have their names in the article. Diagnosis of AD was performed by myself and another neurologist who was not an active member . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials
Jutta Martha Halbekath, Stefanie Schenk, Andreas von Maxen, Gabriele Meyer, and Ingrid Mühlhauser
Arch Intern Med. 2007;167(5):513-514.
EXTRACT | FULL TEXT